Sadra Medical Journal

A Comparison of RAMP Troponin Test Results with Highly Sensitive Laboratory Troponin in Patients Suspected of Acute Myocardial Infarction

Document Type : Original Article

Authors

Neda Soleimani 1
Sahand Mohammadzadeh 1
Hamed Bazrafshan Drissi 2

1 M.D., Assistant Professor of Pathology, Department of pathology, Shiraz Medical School, Shiraz University of Medical Sciences, Shiraz, Iran

2 M.D., Assistant Professor of Cardiology, Cardiovascular Department, Shiraz University of Medical Science, Shiraz, Iran

https://doi.org/10.30476/smsj.2022.94777.1335
Abstract
Introduction: Current guidelines recommend using high-sensitivity troponin (hs-cTnl) assays to manage patients with acute coronary syndrome (ACS) symptoms. Despite this, bedside testing (POC) is commonly used in the emergency room, as it reduces the patient's response time and hospital stay. This study seeks to compare the results of the RAMP- cTnI test with the results of laboratory troponin (hs-cTnl) as the gold standard.
Methods: The present study was performed on 148 patients with suspected acute coronary syndrome referred to Shiraz Namazi Hospital between March and July 2021. Blood samples were taken immediately from patients referred to the emergency department for POC and high-sensitivity troponin test (as gold standard). Enzyme-Linked Fluorescent Assay (ELFA) was used to evaluate troponin (cTnl). The POC test was performed using a RAMP device, which allows the rapid measurement of cTnl in the patient's bedside within 10 minutes using a whole blood sample.
Results: Of the 148 patients, 35 were hs-cTnI positive. Sensitivity, specificity, the positive and negative predictive values of RAMP- cTnI compared to high sensitivity test with 95% confidence interval were 91.42 (93.63-85.84), 94.69% (97.95%-87.55), 84.21% (93.56-77.82) and 97.27% (99.56-87.82), respectively.
Conclusion: The study showed that the quantitatively new RAMP- cTnI method was statistically acceptable with hs - cTnI regarding the accuracy of acute myocardial infarction. RAMP- cTnI was found to be suitable for detecting acute myocardial infarction in the emergency department.

Keywords

Acute Coronary Syndrome
Troponin I
Point-of-Care Testing
  1. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. Eur Heart J. 2012;33(20):2551-67.
  2. Sahand Mohammadzadeh, Nasim Matani, Neda Soleimani, Hamed Bazrafshan drissi, "Comparison of Point-of-Care and Highly Sensitive Laboratory Troponin Testing in Patients Suspicious of Acute Myocardial Infarction and Its Efficacy in Clinical Outcome", Cardiology Research and Practice, vol. 2022, Article ID 6914979, 7 pages, 2022.
  3. Writing Group Members, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133(4):e38-360.
  4. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010;362(23):2155-65.
  5. O'Gara PT, Kushner FG, Ascheim DD, Casey DE Jr, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127(4):e362-425.
  6. Weintraub WS, Daniels SR, Burke LE, Franklin BA, Goff DC Jr, Hayman LL, et al. value of primordial and primary prevention for cardiovascular disease: a policy statement from the American Heart Association. Circulation. 2011;124(8):967-90.
  7. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J. 2014;35(42):2950-9.
  8. GBD 2013 DALYs and HALE Collaborators, Murray CJ, Barber RM, Foreman KJ, Abbasoglu Ozgoren A, Abd-Allah F, et al. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015;386(10009):2145-91.
  9. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2197-223.
  10. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368(21):2004-13.
  11. Yonetsu T, Kakuta T, Lee T, Takahashi K, Kawaguchi N, Yamamoto G, et al. In vivo critical fibrous cap thickness for rupture-prone coronary plaques assessed by optical coherence tomography. Eur Heart J. 2011;32(10):1251-9.
  12. Soleimani N, Mohammadzadeh S, Asadian F. Lipemia interferences in biochemical tests, investigating the efficacy of different removal methods in comparison with ultracentrifugation as the gold standard. Journal of analytical methods in chemistry. 2020 Feb 12;2020.
  13. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139-e228.
  14. Anderson JL, Morrow DA. Acute Myocardial Infarction. N Engl J Med. 2017;376(21):2053-64.
  15. Amsterdam EA, Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, et al. 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139-e228.
  16. Soleimani N, Azadi A, Esmaeili MJ, Ghodsi F, Ghahramani R, Hafezi A, Hosseyni T, Arabzadeh A, Farhadi M, Mohammadzadeh S. Termination of Repeat Testing in Chemical Laboratories Based on Practice Guidelines: Examining the Effect of Rule-Based Repeat Testing in a Transplantation Center. Journal of Analytical Methods in Chemistry. 2021 May 13;2021.
  17. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016;37(3):267-315.
  18. Volz KA, McGillicuddy DC, Horowitz GL, Sanchez LD. Creatine kinase-MB does not add additional benefit to a negative troponin in the evaluation of chest pain. Am J Emerg Med. 2012;30(1):188-90.
  19. Mehta SR, Granger CB, Boden WE, Steg PG, Bassand JP, Faxon DP, et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360(21):2165-75.
  20. Agewall S, Giannitsis E, Jernberg T, Katus H. Troponin elevation in coronary vs. non-coronary disease. Eur Heart J. 2011;32(4):404-11.
  21. Cullen L, Collinson PO, Giannitsis E. Point-of-care testing with high-sensitivity cardiac troponin assays: the challenges and opportunities. Emergency Medicine Journal. 2022 Jan 10.
  22. Juliano M, Wason C. Comparison of Point-of-Care Versus Laboratory Troponin Testing in an Emergency Department Setting. Mil Med. 2017;182(7):e1938-e1940. 
  23. Body R, Almashali M, Morris N, Moss P, Jarman H, Appelboam A, et al. Diagnostic accuracy of the T-MACS decision aid with a contemporary point-of-care troponin assay. Heart. 2019;105(10):768-74. 
  24. Christ M, Geier F, Blaschke S, Giannitsis E, Khellaf M, Mair J, et al. Clinical performance of a new point-of-care cardiac troponin I test. Clin Chem Lab Med. 2018;56(8):1336-44.
Sadra Medical Journal
Volume 10, Issue 2
April 2022
Pages 111-120

Home

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us